The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Abstract
In a randomized study of acute myelocytic leukemia (AML), 352 patients of all ages were treated for remission induction by one of the four regimens: 7 days of cytosine arabinoside (ara-C) by continuous intravenous (i.v.) infusion or bolus injection every 12 hr, together with daunorubicin (DNR) by rapid i.v. injection on days 1, 2, 3; or 5 days of ara-C by infusion or bolus injection and DNR for 2 days only. The regimen of 7 and 3 infusion was significantly superior to the other 3 regimens, resulting in 56% complete remission (CR). For remission maintenance, ara-C was given for 5 days every month and each month one of the following four drugs added on a cyclic rotational basis: thioguanine, cyclophosphamide, CCNU, or DNR. Although ara-C dosage each month was the same, the route of ara-C administration by random allocation was either rapid i.v. bolus or subcutaneous (s.c.) injection. The median duration of CR was significantly longer for s.c. ara-C group: 14 mo for patients less than 60 yr old (versus 8 mo for i.v.) and 31 mo for 60 or older age group (versus 9 mo for i.v.). Patients who received a combination of the best of the four induction regimens (7 and 3 infusion) and the better of the two maintenance schedules (s.c. ara-C) had a median remission duration of 22 mo and a median survival of 35 mo (the longest reported in a prospective randomized trial of therapy for AML). These results establish the validity of an intensive chemotherapy to produce rapid marrow aplasia followed by a sequential maintenance therapy for achieving prolonged disease-free survival in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SNEDECOR, G. W. (1939) · Soil Science · doi:10.1097/00010694-193902000-00006 · Cited by 19,359
Maximum utilization of the life table method in analyzing survival
Cutler, S. J., & Ederer, F. (1958) · Journal of Chronic Diseases · doi:10.1016/0021-9681(58)90126-7 · Cited by 2,870
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship
BRESLOW, N. (1970) · Biometrika · doi:10.1093/biomet/57.3.579 · Cited by 1,411
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
ELLISON, R. R., HOLLAND, J. F., WEIL, M., JACQUILLAT, C., BOIRON, M., BERNARD, J., SAWITSKY, A., ROSNER, F., GUSSOFF, B., SILVER, R. T., et al. (1968) · Blood · doi:10.1182/blood.v32.4.507.507 · Cited by 549
Self-citationChemotherapy of Neoplastic Diseases
Calabresi, P. A., & Welch, A. D. (1962) · Annual Review of Medicine · doi:10.1146/annurev.me.13.020162.001051 · Cited by 419
He, S., Fm, S., & Wilcox, W. S. (1967) · PubMed · Cited by 233
Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878).
Frei, E., Bickers, J. N., Hewlett, J. S., Lane, M., Leary, W. V., & Talley, R. W. (1969) · PubMed · Cited by 214
Clarkson, B., Ohkita, T., Ota, K., & Fried, J. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105553 · Cited by 165
Clarkson, B. D., Fried, J., Strife, A., Sakai, Y., Ota, K., & Ohkita, T. (1970) · Cancer · Cited by 132
Cited by
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Self-citationAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Weick, J., Kopecky, K., Appelbaum, F., Head, D., Kingsbury, L., Balcerzak, S., Bickers, J., Hynes, H., Welborn, J., Simon, Sr., et al. (1996) · Blood · doi:10.1182/blood.v88.8.2841.bloodjournal8882841 · Cited by 411
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
REES, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92674-7 · Cited by 320
Metadata
- Authors
- Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., Cooper, M., Haurani, F., Hutchison, J., Silver, R., Falkson, G., Wiernik, P., Hoagland, H., Bloomfield, C., James, G., Gottlieb, A., Ramanan, S., Blom, J., Nissen, N., Bank, A., Ellison, R., Kung, F., Henry, P., McIntyre, O., & Kaan, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1981-12-01
- Volume
- 58
- Issue
- 6
- Pages
- 1203-1212
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W207118996
- Cited by
- 532
- References
- 12
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. https://app.cochat.ai/papers/10.1182/blood.v58.6.1203.1203
- The paper
- Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., Cooper, M., Haurani, F., Hutchison, J., Silver, R., Falkson, G., Wiernik, P., Hoagland, H., Bloomfield, C., James, G., . . . Kaan, S. (1981). Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. https://doi.org/10.1182/blood.v58.6.1203.1203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.